Tvardi Therapeutics is trading 5.08% up at $1.33 on September 28, 2026, with no specific catalyst identified for the session’s gain.
- Supplied price history shows a sharp rebound following recent declines.
- The latest company-specific news located was a September 24 preclinical-data announcement on its STAT3 inhibitor and ulcerative colitis; it does not establish a reason for the move.
- Broader markets are weaker, and available evidence does not show the stock rising with the market.